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A number of protein kinases are products of oncogenes;
for example, Ret tyrosine kinase is implicated in multiple
endocrine neoplasia type 2, and Met receptor tyrosine
kinase in hereditary papillary renal cancer [1–3]. Other
kinases may be products of tumour suppressor genes. For
example, the gene for MKK4 — one of the dual-speci-
ficity mitogen-activated protein (MAP) kinase kinases that
activate c-Jun amino-terminal kinase/stress-activated
protein kinase (JNK/SAPK) — is mutated or deleted in
some human pancreatic, testis, breast and colon cancer
cell lines [4]. JNK/SAPK activation is thought to induce
apoptosis, so loss of MKK4 may remove one of the normal
checks on cell growth. Expression of death-associated
protein (DAP) kinase (a calcium/calmodulin-dependent
serine/threonine kinase) is lost in some human B-cell lym-
phomas, as well as in several bladder, breast and renal car-
cinoma cell lines [5]. It has been suggested that loss or
inactivation of DAP kinase may convey a selective advan-
tage during the transition of lung cancer cells to a more
aggressive and metastatic phenotype [6]. Recent results
implicate mutations of a serine/threonine kinase and a
dual-specificity phosphatase in some cancer predisposition
syndromes. We shall review these new data and discuss
their implications for tumour suppression. 
The identification of the molecular mechanisms involved
in hereditary cancer syndromes has contributed much to
our understanding of the molecular events underlying
tumorigenesis. For example, familial adenomatous
polyposis coli (FAP), a syndrome characterised by the
formation of multiple benign polyps in the colon and
rectum, from which tumours may develop if left
untreated, is caused by mutation or deletion of the APC
gene. Identification of APC as the gene involved in FAP
has led to a greater understanding of the pathogenesis of
colon cancer, and changes at the APC locus can be used as
a marker to identify patients with a predisposition to
colon cancer [7]. 
A cell may progress towards oncogenic transformation
when one allele of a tumour suppressor gene is inacti-
vated, as a result either of an inherited germline mutation
or an acquired somatic mutation. Inactivation of the
second allele of the gene usually involves a somatic muta-
tion or deletion, resulting in loss of heterozygosity. Loss of
heterozygosity can thus provide an indication of the chro-
mosomal localisation of tumour suppressor genes. A
genetic alteration found frequently in a number of differ-
ent human tumours is loss of heterozygosity at chromo-
some 10q23, which occurs in about 70% of glioblastomas
— the most advanced form of glial tumour — and about
60% of advanced prostate cancers [8]. This led to suspi-
cion that chromosome 10q23 encodes a tumour suppressor
gene. Li et al. [8] recently identified a candidate tumour
suppressor gene in this region which they termed PTEN,
for ‘phosphatase and tensin homologue deleted on chro-
mosome ten’. The same gene was independently isolated
by Steck et al. [9], who called it MMAC1, for ‘mutated in
multiple advanced cancers 1’, and by Li and Sun [10], who
termed it TEP1, for ‘TGFβ-regulated and epithelial cell
enriched phosphatase 1’. For simplicity, we shall refer to
the gene as PTEN.
The PTEN protein shows sequence similarity to protein
tyrosine phosphatases, and Myers et al. [11] have since
demonstrated that PTEN is indeed a phosphatase,
belonging to the subclass of dual-specificity enzymes that
can dephosphorylate serine, threonine or tyrosine residues
on target proteins. PTEN shows a high degree of sub-
strate specificity in vitro, dephosphorylating only the most
acidic peptide substrates tested [11], although physiologi-
cal targets of PTEN remain to be identified. A number of
dual-specificity phosphatases show a preference for
members of the MAP kinase family, but Myers et al. [11]
found that PTEN is unable to dephosphorylate the MAP
kinase ERK2 in vitro. 
PTEN also exhibits extensive sequence homology along
much of its length to the cytoskeletal protein tensin.
Tensin is a Src-homology 2 (SH2) domain-containing
protein which binds to actin and localises to focal adhe-
sions, where it is thought to play a role in the assembly of
signalling complexes. PTEN also has several potential
phosphorylation sites, and a region at its carboxyl terminus
that resembles a motif characteristic of binding sites for
PDZ domains [12]. Interestingly, the APC protein also has
a PDZ-binding domain, through which it interacts with the
PDZ domain of the human homologue of the Drosophila
‘discs large tumour suppressor’ protein [13]. These fea-
tures of PTEN suggest that it may have roles in addition to
that of a phosphatase, perhaps acting as a docking protein
in the assembly of multi-protein signalling complexes. 
The PTEN locus is deleted or mutated, presumably
somatically, in a significant number of tumours and
tumour cell lines, including glioblastomas, malignant
melanomas and prostate, breast and endometrial tumours
[8,9,14–17]. Interestingly, germline mutations in PTEN
also cause Cowden disease (CD), a syndrome charac-
terised by the formation of multiple, benign tumours
(hamartomas) and increased susceptibility to tumours of
the skin, thyroid and breast (Table 1) [18,19]. Mutations
in PTEN have also been identified in patients suffering
from other hamartomatous polyposis syndromes similar to
CD, such as Lhermitte–Duclos disease (LDD) and Ban-
nayan–Zonana syndrome (BZS) [20] (Table 1). An identi-
cal PTEN mutation — C to T at codon 233 — has been
identified in both a family with CD, and a family with
BZS (Table 1). This mutation arose on two different
10q22–23 haplotypes [20], arguing against a common
ancestor or founder effect. The identification of the same
mutation in these two unrelated families suggests that it
may have pleiotropic effects. Alternatively, other factors,
genetic or epigenetic, may be responsible for the pheno-
typic differences seen in the two disorders. 
The genetic lesion responsible for a fourth hamartomatous
polyposis syndrome, Juvenile polyposis syndrome (JPS),
has been putatively localised to chromosome
10q22.3–q24.1 (Table 1). The evidence implicating PTEN
in this syndrome is somewhat controversial. Marsh et al.
[21] excluded both PTEN and chromosome 10q22.3–q24.1
as the susceptibility locus for JPS; however, Lynch et al.
[22] and Olschwang et al. [23] have identified PTEN muta-
tions in some JPS patients. The PTEN mutations identi-
fied both in patients with these cancer predisposition
syndromes, and in primary tumours, have been predicted
to abolish, or significantly reduce, the phosphatase activity
of PTEN. In a number of cases this has in fact been
demonstrated [11], indicating that the enzymatic activity
of PTEN is necessary for its ability to act as a tumour sup-
pressor, and suggesting that PTEN may suppress tumour
cell growth by opposing the actions of protein kinases. 
The family of hamartomatous polyposis syndromes to
which CD, BZS and JPS belong also includes the
Peutz–Jeghers syndrome (PJS). PJS is a rare, dominantly
inherited condition, typified by the formation of intestinal
hamartomatous polyps and mucocutaneous pigmentation
affecting the lips, buccal mucosa and digits (Table 1).
Patients with PJS also have an increased susceptibility to
tumours of the gastrointestinal tract, breast, testis and
ovary. A locus for this condition was recently mapped 
to chromosome 19p. Hemminki et al. [24] have since
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Table 1
Phenotypes and genes involved in hamartomatous polyposis syndromes.
Syndrome Phenotype Chromosomal locus Examples of identified mutations References
and predicted effects
Cowden disease Multiple hamartomatous lesions 10q23.3 PTEN codon 123, A to G; His to Arg [18,19]
(CD) of the skin, mucous membranes, PTEN codon 124, T to C; Cys to Arg
breast and thyroid; hamartomatous PTEN codon 129, G to A; Gly to Glu
polyps of the intestine; pre- PTEN codon 130, C to T; Arg to STOP
disposition to tumours of the PTEN codon 233, C to T; Arg to STOP
skin, thyroid and breast.
Lhermitte–Duclos Central nervous system manifestation 10q23.3 PTEN codon 157, G to T; Glu to STOP [19]
disease (LDD) of CD; additional symptoms include
ataxia, macrocephaly and dysplastic
cerebellar gangliocytomatosis.
Bannayan–Zonana Mental retardation; macrocephaly; 10q23.3 PTEN codon 170, T to A; Ser to Arg [20]
syndrome (BZS) thyroid disease; lipomatosis; vascular PTEN codon 233, C to T; Arg to STOP
malformations; speckled pigmentation
of the penis.
Juvenile polyposis Multiple hamartomatous lesions in the 10q22.3–q24.1 PTEN codon 35, T to G; Arg to Met [22,23]
syndrome (JPS) colon, stomach and small bowel; also PTEN codon 232, 1 bp deletion; frameshift
associated with congenital malformations,
mental retardation and predisposition to
tumours of digestive tract and pancreas.
Peutz–Jeghers Hamartomatous polyps of the intestine; 19p13.3 LKB1 codon 57, G to T; Glu to STOP [24]
syndrome (PJS) melanin spots of the lips, buccal mucosa LKB1 codon 60, C to G; Tyr to STOP
and digits; predisposition to tumours of the LKB1 codons 307–370, 188 bp deletion;
colon, stomach, pancreas and ovary. frameshift
identified germline mutations in a gene residing on chro-
mosome 19p in patients with PJS. This previously identi-
fied but unmapped gene, termed LKB1, encodes a
serine/threonine kinase originally found to be expressed in
human foetal liver. LKB1 exhibits strong sequence similar-
ity to a Xenopus serine/threonine kinase, XEEK1 for
‘Xenopus egg and embryo kinase’ [25]. XEEK1 is a cyto-
plasmic kinase with a narrow substrate specificity,
expressed in Xenopus oocytes and fertilised eggs but barely
detectable during gastrulation and later embryonic stages.
The mutations identified in LKB1 in patients with PJS are
predicted to abolish some or all of the kinase activity of the
protein, although this remains to be formally demonstrated. 
That PTEN and LKB1 are mutated in hamartomatous
polyposis syndromes may give some clue to the cellular
roles of their products. As hamartomas are benign, disor-
ganised masses of cells and tissues, PTEN and LKB1 may
function in normal tissues to guide cellular interactions,
ensuring that tissues and organs are correctly formed. Het-
erozygous mutation of PTEN or LKB1, in combination with
loss of heterozygosity of the wild-type allele, might cause a
tendency to proliferation and tissue disorganisation,
leading to the formation of hamartomas. This aberrant pro-
liferation and disorganisation may be the background on
which malignant transformation then occurs as a result of
somatic mutation of other tumour suppressor genes and/or
oncogenes. It remains to be seen whether PTEN and
LKB1 act in the same signal transduction pathway.
Despite the lack of available information on the actual
functions and physiological substrates of the enzymes
encoded by PTEN and LKB1, the recent evidence
implicating them in the cancer predisposition syndromes
CD, BZS, JPS and PJS should facilitate the early diagnosis
of both familial and sporadic cases of these disorders.
Determination of the normal cellular functions of the
enzymes PTEN and LKB1 should also provide a greater
understanding of the pathogenesis of the various tumours
associated with these syndromes.
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